Initial Promising Data With a Systemically Administered TLR 7 & 8 Coagonist (EIK1001)
Time: 9:45 am
day: Conference Day 2
Details:
- Understand the scientific rationale behind EIK1001, a systemically administered agonist of toll-like receptors 7 and 8
- Analyze single-agent activity data as well as activity in combination with anti-PD-1 agents across multiple solid tumor types
- Discuss the program advancing into late stage development
